The FDA will consider the approval of the biologics license application next month.
An original version of this article was published online by sister publication NeurologyLive.
Findings from a new study demonstrated that pegunigalsidase alfa, or PRX-102, was well-tolerated among patients with Fabry disease.
Furthermore, patients were noted to be stable in their clinical presentations following treatment course.
These findings were announced last week by Protalix Biotherapeutics and Chiesi Global Rare Diseases.
The 12-month open-label, switch-over, phase 3 BRIGHT study included 30 patients with Fabry disease previously treated with a commercially available enzyme replacement therapy (ERT), such as agalsidase alfa or agalsidase beta for at least 3 years prior and were on a stable dose administered every 2 weeks.
After receiving treatment with pegunigalsidase alfa 2 mg/kg every 4 weeks, no patients developed treatment-induced anti-drug antibodies (ADA).
No Fabry clinical events were reported during the study either.
Plasma lyso-Gb3 concentrations remained stable during the study with a mean change of 3.01 nM from baseline (19.36 nM) to week 52 (22.23 nM).
During the 52-week treatment period, mean absolute change of Estimated Glomerular Filtration Rate (eGFR) values remained stable, with a mean change from baseline of –1.27 mL/min/1.73 m2.
Researchers also found that patient perception of their own health remained high and stable throughout the study duration.
This was indicated by a survey using the Quality of Life EQ-5D-5L questionnaire, with overall health mean scores of 78.3 (±3.1) and 82.1 (±2.9) at baseline and week 52, respectively, on a 0 to 100 scale.
Using the short-form Brief Pain Inventory (BPI) questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at week 52, as compared to baseline. These results remained stable throughout the study, and pain-related results showed no increase and/or relapse in pain.
The most common Fabry disease symptoms observed were acroparesthesia, heat tolerance, angiokeratomas, and hypohydrosis.
Each patient received at least 1 dose of pegunigalsidase alfa, 29 of which completed the 12-month study.
Of these 29 patients, 28 received the intended regimen of 2 mg/kg every 4 weeks throughout the study, while 1 patient was switched to pegunigalsidase alfa 1 mg/kg every 2 weeks per protocol.
"The results indicate that this investigational therapy is well tolerated and potentially an effective treatment for adult patients living with Fabry disease," Einat Brill Almon, PhD, senior vice president and chief development officer, Protalix, said in a statement.
"We are encouraged to see that all of the patients who completed this study chose to enroll in the long-term extension study,” she continued. “Currently, 80% of the patients enrolled in the BRIGHT study have been treated with this treatment regimen for over 2 years. We look forward to advancing this study and further evaluating the results."
The treatment received fast track designation in 2018 and continued to make headlines in August 2020 when the company announced that the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA).
At the time, the company announced a prescription drug user fee act (PDUFA) date for January 27, 2021, but in November, the FDA extended the action date by 3 months to April 27, 2021.3
The BLA was supported by a comprehensive set of data compiled from the company’s completed phase 1/2 clinical trial as well as the related extension study succeeding the phase 1/2 clinical trial, interim data from the phase 3 BRIDGE switch-over study, and safety data from the on-going clinical studies of pegunigalsidase alfa in patients receiving 1 mg/kg every other week.